Ongoing treatment(s)-Biological/Targeted therapy - Page 2 of 3 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological/Targeted therapy Posts on Medivizor

Long-term outcomes of radioimmunotherapy in patients with follicular lymphoma

Posted by on Oct 5, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term outcomes of radioimmunotherapy following first-line (primary) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced-stage follicular lymphoma (FL). This study concluded that this treatment approach is effective and well-tolerated in...

Read More

Evaluating the effectiveness of stem cell transplant in patients with follicular lymphoma with early treatment failure

Evaluating the effectiveness of stem cell transplant in patients with follicular lymphoma with early treatment failure

Posted by on Sep 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...

Read More

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Posted by on Sep 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...

Read More

Evaluating the impact of rituximab treatment on follicular lymphoma transformation

Evaluating the impact of rituximab treatment on follicular lymphoma transformation

Posted by on Aug 24, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of rituximab (Rituxan) treatment on the risk of lymphoma transformation (development of aggressive lymphoma) in patients with follicular lymphoma (FL). They concluded that this risk can be significantly reduced by the use of first-line (primary treatment) rituximab. Some background FL is the second most...

Read More

Chemotherapy after radiotherapy for early-stage follicular lymphoma

Chemotherapy after radiotherapy for early-stage follicular lymphoma

Posted by on Jul 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...

Read More

Long-term outcomes of ibrutinib plus rituximab for relapsed or refractory mantle cell lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More